"Smart" Drug Delivery: A Window to Future of Translational Medicine

Overview

Journal Front Chem

Specialty Chemistry

Date 2023 Jan 23

PMID 36688039

Authors

Abhilash Rana

Meheli Adhikary

Praveen Kumar Singh

Bhudev C Das

Seema Bhatnagar

Affiliations

Soon will be listed here.

Abstract

Chemotherapy is the mainstay of cancer treatment today. Chemotherapeutic drugs are non-selective and can harm both cancer and healthy cells, causing a variety of adverse effects such as lack of specificity, cytotoxicity, short half-life, poor solubility, multidrug resistance, and acquiring cancer stem-like characteristics. There is a paradigm shift in drug delivery systems (DDS) with the advent of smarter ways of targeted cancer treatment. Smart Drug Delivery Systems (SDDSs) are stimuli responsive and can be modified in chemical structure in response to light, pH, redox, magnetic fields, and enzyme degradation can be future of translational medicine. Therefore, SDDSs have the potential to be used as a viable cancer treatment alternative to traditional chemotherapy. This review focuses mostly on stimuli responsive drug delivery, inorganic nanocarriers (Carbon nanotubes, gold nanoparticles, Meso-porous silica nanoparticles, quantum dots ), organic nanocarriers (Dendrimers, liposomes, micelles), antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC) based SDDSs for targeted cancer therapy and strategies of targeted drug delivery systems in cancer cells.

Citing Articles

Alginate Hydrogel Beads with a Leakproof Gold Shell for Ultrasound-Triggered Release.

Flowers M, Paulsen A, Kaiser C, Tuma A, Lim H, Ogle B Pharmaceutics. 2025; 17(1).

PMID: 39861779 PMC: 11768098. DOI: 10.3390/pharmaceutics17010133.

A Modular Approach to Obtain HER2-Targeting DM1-Loaded Nanoparticles for Gastric Cancer Therapy.

Zhang H, Guo L, Li X, Liu H, Zhao Z, Ji G ACS Omega. 2024; 9(49):48598-48606.

PMID: 39676924 PMC: 11635515. DOI: 10.1021/acsomega.4c07442.

A Review of Recent Developments in Biopolymer Nano-Based Drug Delivery Systems with Antioxidative Properties: Insights into the Last Five Years.

Stevanovic M, Filipovic N Pharmaceutics. 2024; 16(5).

PMID: 38794332 PMC: 11125366. DOI: 10.3390/pharmaceutics16050670.

Colloidal and Biological Characterization of Dual Drug-Loaded Smart Micellar Systems.

Herman H, Rata D, Cadinoiu A, Atanase L, Hermenean A Polymers (Basel). 2024; 16(9).

PMID: 38732658 PMC: 11085147. DOI: 10.3390/polym16091189.

Stimulus triggered release of actives from composite microcapsules based on sporopollenin from .

Lecoeuche M, Borovicka J, Dyab A, Paunov V RSC Adv. 2024; 14(15):10280-10289.

PMID: 38549792 PMC: 10975325. DOI: 10.1039/d4ra00236a.

References

Al Faraj A, Shaik A, Shaik A . Magnetic single-walled carbon nanotubes as efficient drug delivery nanocarriers in breast cancer murine model: noninvasive monitoring using diffusion-weighted magnetic resonance imaging as sensitive imaging biomarker. Int J Nanomedicine. 2015; 10:157-68. PMC: 4278781. DOI: 10.2147/IJN.S75074. View

Zhu L, Kate P, Torchilin V . Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012; 6(4):3491-8. PMC: 3337349. DOI: 10.1021/nn300524f. View

Madaan K, Kumar S, Poonia N, Lather V, Pandita D . Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014; 6(3):139-50. PMC: 4097927. DOI: 10.4103/0975-7406.130965. View

Wen R, Umeano A, Chen P, Farooqi A . Polymer-Based Drug Delivery Systems for Cancer. Crit Rev Ther Drug Carrier Syst. 2018; 35(6):521-553. DOI: 10.1615/CritRevTherDrugCarrierSyst.2018021124. View

Rahamathulla M, Bhosale R, Osmani R, Mahima K, Johnson A, Hani U . Carbon Nanotubes: Current Perspectives on Diverse Applications in Targeted Drug Delivery and Therapies. Materials (Basel). 2021; 14(21). PMC: 8588285. DOI: 10.3390/ma14216707. View

Guo L, Shi D, Shang M, Sun X, Meng D, Liu X . Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA. Drug Deliv. 2022; 29(1):316-327. PMC: 8765274. DOI: 10.1080/10717544.2022.2026532. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Kang M, Yoo H, Kwon Y, Yoon H, Lee S, Kim S . Design of Multifunctional Liposomal Nanocarriers for Folate Receptor-Specific Intracellular Drug Delivery. Mol Pharm. 2015; 12(12):4200-13. DOI: 10.1021/acs.molpharmaceut.5b00399. View

Chen H, Wang Z, Zong S, Chen P, Zhu D, Wu L . A graphene quantum dot-based FRET system for nuclear-targeted and real-time monitoring of drug delivery. Nanoscale. 2015; 7(37):15477-86. DOI: 10.1039/c5nr03454j. View

10.

Rajasekhar Reddy R, Raghupathi K, Torres D, Thayumanavan S . Stimuli Sensitive Amphiphilic Dendrimers. New J Chem. 2013; 36(2):340-349. PMC: 3770314. DOI: 10.1039/C2NJ20879B. View

11.

Reddy J, Dorton R, Westrick E, Dawson A, Smith T, Xu L . Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007; 67(9):4434-42. DOI: 10.1158/0008-5472.CAN-07-0033. View

12.

Pan Y, Chen Y, Wang D, Wei C, Guo J, Lu D . Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release. Biomaterials. 2012; 33(27):6570-9. DOI: 10.1016/j.biomaterials.2012.05.062. View

13.

Kenchegowda M, Rahamathulla M, Hani U, Begum M, Guruswamy S, Osmani R . Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review. Molecules. 2022; 27(1). PMC: 8746670. DOI: 10.3390/molecules27010146. View

14.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

15.

Hu J, Fu S, Peng Q, Han Y, Xie J, Zan N . Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation. Int J Pharm. 2016; 516(1-2):313-322. DOI: 10.1016/j.ijpharm.2016.11.047. View

16.

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

17.

Xu H, Li Z, Si J . Nanocarriers in gene therapy: a review. J Biomed Nanotechnol. 2015; 10(12):3483-507. DOI: 10.1166/jbn.2014.2044. View

18.

Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P . Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018; 8(6):916-931. PMC: 6048407. View

19.

Vives E, Schmidt J, Pelegrin A . Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008; 1786(2):126-38. DOI: 10.1016/j.bbcan.2008.03.001. View

20.

Thiviyanathan V, Gorenstein D . Aptamers and the next generation of diagnostic reagents. Proteomics Clin Appl. 2012; 6(11-12):563-73. PMC: 4021847. DOI: 10.1002/prca.201200042. View